Detecting Dementia Before it Happens
99.6% of clinical trials for Dementia have not worked. Drugs used today do not address the root causes but only alleviate symptoms for a few years. To discover drugs that work, pharmaceutical companies have shifted clinical trial towards earlier stage patients. However, the putative early stage of Dementia, Mild Cognitive Impairment (MCI), progresses to actual Dementia at less than 15% per year, meaning a clinical trial needs to enrol many patients and last many years to show effectiveness. We have developed algorithms that can find the patients who convert next year with an accuracy of 75%, meaning that clinical trials need fewer patients for less time, drastically decreasing cost.
Alejandro (Sasha) Vicente Grabovetsky is a Cognitive Neuroscientist specialising in memory. He graduated with a BA and a PhD from Cambridge University and did his Post-Doc at the Donders Centre for Cognitive Neuroimaging. He left academia and joined the Entrepreneur First program in London. There, he met his co-founder, livier van den Biggelaar, a Software Engineer who built complex Machine Learning systems in his PhD at the University of Brussels and in industry.